Last reviewed · How we verify
Verinurad prolonged release HPMC capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Verinurad prolonged release HPMC capsule (Verinurad prolonged release HPMC capsule) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Verinurad prolonged release HPMC capsule TARGET | Verinurad prolonged release HPMC capsule | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Verinurad prolonged release HPMC capsule CI watch — RSS
- Verinurad prolonged release HPMC capsule CI watch — Atom
- Verinurad prolonged release HPMC capsule CI watch — JSON
- Verinurad prolonged release HPMC capsule alone — RSS
Cite this brief
Drug Landscape (2026). Verinurad prolonged release HPMC capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/verinurad-prolonged-release-hpmc-capsule. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab